Rampart Appoints Rob Williamson as Chief Revenue Officer

February 12, 2026—Rampart, a Birmingham, Alabama–based medical device company focused on radiation safety in the interventional suite, announced that Rob Williamson has been appointed Chief Revenue Officer, effective March 1, according to a company press release. Williamson, who previously served on Rampart’s Board of Directors, will lead the company’s United States sales organization with a focus on revenue growth, field execution, and team expansion. Brian Chambless will continue as Chief Commercial Officer, overseeing global commercial strategy.

The leadership change comes as Rampart seeks to expand adoption of its radiation safety platform amid growing attention to occupational exposure and orthopedic strain among interventional specialists. Physicians and staff in catheterization laboratories and other procedural settings face some of the highest occupational radiation exposure levels in medicine, and traditional 20- to 30-pound lead aprons have been associated with orthopedic injury.

“Rampart is entering an important stage of development as we see signs of change in the standard of care for radiation and orthopedic protection in the interventional suite,” said Tom Livingston, President and CEO of Rampart. “We are investing intentionally in leadership and execution to accelerate adoption of our radiation safety platform. Rob’s experience scaling high-performing sales organizations in intense growth environments makes him the right leader for this next phase.”

Williamson brings more than 25 years of medical device leadership experience, including senior commercial roles at Medtronic, Covidien, ev3, FoxHollow, and Bard. Most recently, he served as Vice President of Sales at Shockwave Medical, where he built and led a field organization of more than 300 people and helped scale the company to more than $500 million in annual revenue.

“Serving on the Board gave me a front-row seat to the strength of Rampart’s team and the momentum building in the market,” Williamson said. “This is a company with a clear mission and a differentiated platform. I’m energized to lead the sales organization and help bring this solution to more health care teams across the country.”

Rampart’s portfolio includes completely lead-free radiation-attenuating systems designed to provide total-body shielding for the procedural team. The company reports that its proprietary ClearShield attenuation material provides 1 mm of lead equivalence while maintaining workflow and supply chain control through in-house manufacturing. Rampart systems are deployed in academic institutions and United States health care systems and are distributed globally.